Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
This week, MGA released a new white paper by Alex Brill and Christy Robinson looking at the long-term effects of Medicare price negotiations on drug competition
Oregon’s Measure 118: The Turnover Tax Is the Worst
Next week, Oregon voters will weigh in on a tax-related ballot measure with concerning repercussions.
Alex Brill on Single-Payer Health Care System and Drug Costs
Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.
Demand for FDA Action Amid Shuffle
“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
